CClinicalTrials.gg
CompletedNCT01771302Updated Aug 23, 2021

Efficiency of PRGF-Endoret in Combination With a Bone Graft in Lateral Sinus Floor Elevation

An interventional study of Bio-Oss and calcium phosphate ceramic in Sinus Floor Augmentation, sponsored by Fundación Eduardo Anitua. Completed at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-23.

Sponsored by Fundación Eduardo Anitua · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized clinical study investigates the efficiency of plasma rich in growth factors (PRGF-Endoret) in combination with bone grafts in the healing of bone and soft tissues after the performance of lateral sinus floor elevation.

The hypothesis of this study is that the use of PRGF-Endoret will produce similar bone formation regardless the type of bone graft.

02

Conditions studied

  • Sinus Floor Augmentation

Keywords

  • PRGF-Endoret
  • Bone graft
  • Maxillary sinus
  • Vertical bone augmentation
03

In context

Lead sponsor

Fundación Eduardo Anitua is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients over 18 years
  • Patients requiring implant prostheses oral rehabilitation.
  • Patients with insufficient residual height in posterior maxilla requiring a sinus lift procedure to insert the implants

Exclusion criteria

Exclusion Criteria:

  • Not having complete the informed consent form.
  • Sinusitis.
  • Alcoholism.
  • Suffering severe haematological disorder or disease.
  • Be undergoing or having received radiotherapy, chemotherapy or immunosuppressive therapy, corticosteroids and / or anticoagulants, 30 days prior to the study inclusion.
  • In usual treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or other anti-inflammatory drugs.
  • Background of chronic hepatitis or liver cirrhosis.
  • Diabetes mellitus with poor metabolic control (glycosylated hemoglobin above 9%)
  • Patients undergoing dialysis.
  • Presence of malignant tumors, hemangiomas or angiomas in the extraction area.
  • History of ischemic heart disease in the last year.
  • Pregnancy or intention to become pregnant during the study follow-up period.
  • Metabolic bone disease
  • Patients taking bisphosphonates drugs both orally and intravenously.
  • In general, any inability to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Bio-Oss

    the xenograft is of bovine origin where the organic phase has been eliminated.

    Device: Bio-Oss

  • Experimental
    calcium phosphate ceramic

    is a calcium phosphate biomaterial

    Device: calcium phosphate ceramic

Interventions

  • DeviceBio-Oss

    It is a bone substitute of bovine origin

  • Devicecalcium phosphate ceramic

    It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature

06

What researchers measure

Primary outcomes

  1. Percentage of newly-formed bone

    The histomorphometrical analysis of the biopsies taken after 6 months of surgical intervention (time for dental implants insertion) will be performed to calculate the primary outcome

    Time frame: 6 months after surgical intervention

Secondary outcomes

  1. Bone density

    This data will be measured on the cone-beam CT scanners obtained at baseline and after 6 months of healing

    Time frame: at baseline and after 6 months of intervention

  2. Insertion torque

    At the time of implant insertion and initial insertion torque will be registered

    Time frame: 6 months after surgical intervention

  3. Percentage of residual graft

    The histological analysis will determine the percentage of residual graft after 6 months of surgery.

    Time frame: 6 months after surgical intervention

  4. Pain index

    This will evaluate the intensity of pain the patient suffered due to the surgical intervention.

    Time frame: 7 days, 15 days, 1 month, 2 months, 6 months and 12 months after surgical intervention

  5. Healing index

    This index will evaluate the soft tissue healing.

    Time frame: 7 days, 15 days and 1 month after surgical intervention

  6. Infection

    Notify the infection of the graft material

    Time frame: 7 days, 15 days, 1 month, 2 months, 6 months and 12 months after surgical intervention

07

Study locations

1 site
  • Clinica Eduardo Anitua
    Vitoria, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01771302
Lead sponsor
Fundación Eduardo Anitua
Collaborators
Biotechnology Institute IMASD
Responsible party
Sponsor
First posted
Jan 18, 2013
Start date
Jan 2013
Primary completion
Apr 2014
Completion
Apr 2014
Last update
Aug 23, 2021

Study contacts

Eduardo Anitua, MD, DDS, PhD
principal investigator · Clinica Eduardo Anitua

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion